What Puregon Treats: Main Uses and Benefits

Puregon is applied across domains where additional symptomatic support is needed to address conditions presenting with systemic or localized discomfort associated with fertility challenges. It is commonly used across conditions presenting with acute episodes like anovulatory infertility and deficient sperm production, and its relevance in contexts involving heightened systemic burden during Assisted Reproduction Techniques (ART).

The medicine is commonly used to help with follicle growth and egg maturation in women, and it is considered relevant for easing systemic imbalance in men with hormonal deficiencies. The support provides assistance with maintaining functional stability when symptoms interfere with routine activities.

“It assists with maintaining functional stability for patients undergoing procedures that create noticeable physiological strain.”

Quick Fact: Relief for Systemic Imbalance

For women, the therapeutic domain is relevant for easing symptoms associated with the conditions requiring symptomatic support for achieving ovulation and follicular development during ART procedures. For men, it is used for managing symptoms linked to organ-specific functional stress in specific hormonal deficiency cases. This support contributes to easing the overall symptom load and may help patients cope more steadily with symptom fluctuations.

Regulatory References

1. European Medicines Agency (EMA) product overview

Official Eligibility Rules for Follitropin Beta

The eligibility profile for Пурегон (follitropin beta) is strictly defined by regulatory authorities, focusing on specific adult populations while establishing clear prohibitions for others. The medicine is indicated for adult females with anovulatory infertility unresponsive to clomifene, or those undergoing Controlled Ovarian Hyperstimulation (COH) for ART. It is also indicated for adult males with deficient spermatogenesis due to hypogonadotrophic hypogonadism.

Contraindicated Populations	Use Status
Patients with Hypersensitivity to the drug or excipients	Contraindicated
Females who are Pregnant or Breastfeeding	Contraindicated
Patients with Tumours (ovary, breast, pituitary, etc.)	Contraindicated
Patients with Primary Gonadal Failure (high endogenous FSH)	Contraindicated
Females with undiagnosed vaginal bleeding or anatomical infertility	Contraindicated

Special Population Status	Eligibility Rule
Pediatric (Under 18) or Postmenopausal Women	Not Indicated/Not Established
Renal or Hepatic Impairment	Pharmacokinetics Not Determined

Use is also conditional, requiring the exclusion or treatment of uncontrolled non-gonadal endocrine disorders prior to initiation. For women with severe obesity or a history of thrombosis, treatment requires a careful benefit-risk assessment.

Interactions with other medicines and products

The interaction profile for follitropin beta is primarily defined by the necessary co-administration with other hormonal agents required for fertility treatments, and a mandatory restriction on physical mixing. Official regulatory documents note that formal drug-drug interaction studies have not been conducted to evaluate potential pharmacokinetic effects.

---

Documented Co-Administration Patterns

Treatment with follitropin beta is part of a therapeutic regimen that requires co-administration with specific medications, which represents documented pharmacodynamic interactions:

• Human Chorionic Gonadotropin (hCG): This agent is required for co-administration following follitropin beta to trigger the final stage of follicular maturation, which is an essential part of the treatment protocol.
• GnRH Agonists or Antagonists: These hormonal agents are commonly co-administered as part of controlled ovarian stimulation protocols to manage the timing of the menstrual cycle.

---

Pharmacokinetic and Metabolic Status

Official regulatory prescribing information explicitly states that formal studies to assess interactions mediated by metabolic enzymes, such as the Cytochrome P450 system, or drug transporters have not been performed. Consequently, there is no official documentation regarding substances that increase, decrease, or otherwise alter the systemic exposure of follitropin beta. No interactions with food, alcohol, or herbal products are formally documented in the label’s interaction sections.

---

Administration Restrictions

A critical restriction specified in regulatory labeling is a prohibition on physical co-mixing. The solution must not be mixed with any other medicinal product in the same syringe or vial. This mandatory rule is enforced due to the absence of documented compatibility data.

Receptor-Specific Agonism and Target Cell Activation

The entire mechanism of follitropin beta is defined by its role as a specific agonist for the FSH Receptor (FSHR), a protein found predominantly on ovarian granulosa cells and testicular Sertoli cells. This high-affinity binding initiates a signal transduction cascade coupled to the cyclic AMP (cAMP) pathway within the cell. This domain describes the core targets and the initial molecular interaction that triggers the internal cellular response.

---

Cascade of Proliferation and Hormone Synthesis

Activation of the FSHR cascade directly drives the proliferation and differentiation of these gonadal support cells. In females, this leads to metabolic shifts that enhance steroidogenesis, causing a substantial increase in localized estrogen synthesis. In males, it promotes spermatogenesis by stimulating the production of local factors like Androgen-Binding Protein (ABP). This domain translates the molecular activation into the physiological consequence of reproductive cell development.

---

Functional Limitation and Sequential Dependence

The FSH-driven mechanism focuses on the growth and maturation phase. While it promotes the development of reproductive structures, it cannot induce the final events. The completion of the full reproductive cycle requires subsequent intervention via the Luteinizing Hormone (LH) pathway (or its analogue, hCG) to trigger processes like final follicular rupture or luteinization.

Puregon (follitropin beta) is typically administered as a subcutaneous injection (under the skin) using the Puregon Pen device. The initial injection should be performed under the supervision of a healthcare professional. After proper training, you or a partner may perform the daily injections at home, adhering strictly to the prescribed dosage and schedule.

---

Preparation and Injection

1. Preparation: Always wash and dry your hands thoroughly. Retrieve the Puregon cartridge from the refrigerator and inspect the solution; it should be clear and colorless. Do not use the cartridge if the solution is discolored or contains particles.
2. Assembly: Load the cartridge into the Puregon Pen and attach a new, sterile pen needle. The cartridge is designed for use exclusively with the Puregon Pen.
3. Priming (New Cartridge): If using a new cartridge, prime the pen to ensure proper flow by setting a small dose (e.g., one click) and pushing the injection button while the needle points upward, until a droplet appears at the tip. This confirms the needle is clear of air.
4. Dose Setting: Turn the dosage knob to your prescribed dose. If you accidentally dial past the correct dose, do not turn the knob backward, as this may waste medication. Instead, continue turning until the knob stops, push the injection button fully to reset, and then dial the dose again from zero.
5. Injection Site: The recommended site for subcutaneous injection is the lower abdomen or the upper thigh. To prevent skin problems like lipoatrophy, alternate the exact injection site each day. Clean the injection area with an alcohol swab and allow it to dry.
6. Administration: Pinch a fold of skin at the cleansed site. Insert the entire needle straight into the skin (typically at a 90° angle). Push the injection button all the way down until the dosage window reads '0.' Hold the needle in the skin for about five seconds after the zero appears before withdrawing it. Apply gentle pressure to the site if needed.

---

Storage and Disposal

Puregon cartridges must be stored in the refrigerator between 2°C and 8°C (36°F and 46°F) and must not be frozen. Once the cartridge has been punctured (in use), it may be stored at or below 25°C for a maximum of 28 days. Used needles must be removed after each injection and disposed of in a proper sharps container. Do not reuse needles.

Research Evidence / Overview of Studies for Пурегон (Follitropin Beta)

---

Evidence for use in Controlled Ovarian Stimulation (COS) for ART

This section summarizes the available clinical trials and studies that explored the use of Пурегон (follitropin beta) for women undergoing assisted reproductive technology (ART) procedures, such as In Vitro Fertilization (IVF). Studies focused on outcomes related to oocyte yield and outcomes reported following the transfer of a developing embryo. The studies involved populations of adult women participating in an ART program who were evaluated during treatment.

Research explored how the medication affected outcomes reflecting daily functioning or activity level of the ovaries. Findings describe patterns observed in the studies where the use of this drug was studied in relation to the development of multiple ovarian follicles, a process monitored during COS.

What remains uncertain is the long-term impact on the health of women and children, as follow-up durations were limited in most primary trials. Comparative evidence is lacking for a direct comparison against all other available treatment options over the long term. Also, results apply only to the populations studied, meaning individual responses may vary widely depending on specific health and fertility characteristics.

---

Evidence for use in Inducing Ovulation in Anovulatory Women

This section outlines the structure of evidence from clinical trials evaluating the use of this drug to help stimulate follicular development and trigger ovulation in women diagnosed with anovulatory infertility. Studies explored outcomes related to achieving ovulation and subsequent pregnancies, often focusing on ovulation rates.

Studies report how symptoms evolved in the observed populations, indicating that the use of this drug, often in a low-dose step-up regimen, was associated with patterns of ovulation rates in women with WHO Group II anovulation. Studies monitored the incidence of single versus multiple follicular development.

Evidence is limited regarding the exact comparative evidence of follitropin beta versus other hormonal products when looking specifically at pregnancy and live birth rates. Long-term effects are not fully established regarding recurrence of anovulation after treatment is stopped.

---

What is Still Uncertain about Пурегон

This section synthesizes the main evidence gaps, inconsistent findings, and areas where more research is needed. Evidence quality varies across studies, particularly when comparing different hormonal preparations, and findings were mixed depending on the specific trial design and population studied. Sample sizes were modest in many trials, which limits the ability to draw definitive conclusions about rare or long-term effects. Research is ongoing to improve the overall evidence landscape.

Common questions about Пурегон (FAQ)

Q: What is the difference between Puregon and other stimulation medicines?

Puregon contains follitropin beta, which is a highly pure, recombinant (man-made) version of Follicle-Stimulating Hormone (FSH). Its action is specific to the FSH receptor in the body. While its chemical class is defined in official documents, formal, long-term comparative efficacy studies against all other available treatment options are limited.

Q: Why is Puregon administered by injection and not taken as tablets?

The active ingredient, follitropin beta, is a protein hormone. Like many protein-based medications, Puregon is formulated as an injectable solution because if it were taken as a tablet, the medication would likely be broken down by the digestive system before it could be effectively absorbed into the bloodstream.

Q: How quickly does Puregon start to act?

Pharmacokinetic studies, which track how the body processes the medicine, show that the concentration of follitropin beta in the blood reaches its peak relatively quickly. Following a subcutaneous injection, the maximum concentration is typically reached within approximately 8 to 20 hours.

Q: Can Puregon affect mood or cause headaches?

Official regulatory information documents list headache as a common adverse reaction (affecting 1 in 10 to 1 in 100 patients). However, the specific effects on mood or emotional state are not commonly listed among the officially documented side effects of follitropin beta.

Q: Are there studies on the effect of Puregon on the fetus?

Follitropin beta is contraindicated (not to be used) during pregnancy. While some animal studies reported adverse effects on reproduction, no birth defects were observed in those specific studies. Limited human data currently do not suggest an increased risk of malformative toxicity, but controlled human studies are lacking.

Q: Is it true that Puregon injections can be painful?

Reactions at the injection site, which can include pain, bruising, redness, or localized swelling, are officially classified as Very Common adverse reactions, meaning they affect 1 in 10 patients or more. This type of reaction is frequently observed where the injection is administered.

Q: What do studies say about the likelihood of pregnancy with Puregon?

Clinical studies evaluate the drug's use in relation to outcomes like ovulation rates and oocyte yield, which are key steps toward pregnancy. Official documents advise that study results apply only to the populations included in the trials, and individual response to fertility treatment can vary widely depending on personal health factors.

Q: How does Puregon affect egg quality?

The active ingredient, follitropin beta, works to promote the growth and maturation of ovarian follicles, which house the egg cells. This is achieved through stimulating cellular proliferation and hormone synthesis within the ovary. Regulatory documentation focuses on the development and maturation of follicles.

Q: Do I need to change anything in my diet when I use Puregon?

Official regulatory prescribing information does not formally document any specific interactions between follitropin beta and food. Patients are generally advised to follow any diet or lifestyle recommendations provided by their healthcare provider.

Q: Is it possible to drink alcohol during treatment with Puregon?

Official regulatory prescribing information does not formally document any interactions between follitropin beta and alcohol.

Q: Is it possible to travel with Puregon?

When transporting the medicine, it is necessary to strictly follow the required storage conditions described in the patient information. Unopened cartridges require continuous refrigeration between 2 C and 8 C. Once the cartridge is punctured for use, it may be stored at a temperature not exceeding 25 C for a maximum of 28 days.

Q: How does Puregon affect weight?

Significant or rapid weight gain is not listed as a common, general side effect of follitropin beta. However, official safety information highlights that rapid weight gain is an important warning sign of a serious complication called Ovarian Hyperstimulation Syndrome (OHSS).

Q: Is it true that Puregon can cause multiple pregnancy?

Official documents state that the use of gonadotropins, including follitropin beta, is associated with an increased incidence of multiple gestations, such as twins or triplets. This is a known potential risk of controlled ovarian stimulation, and patients are advised of this potential before starting treatment.

Q: For what purposes is Puregon used in men?

In adult males, follitropin beta is indicated for those with deficient sperm production due to a hormone deficiency known as hypogonadotrophic hypogonadism. The general purpose is to stimulate the testicular Sertoli cells to promote spermatogenesis (sperm development).

Q: Is it safe to use Puregon if I have thyroid problems?

Official safety information states that follitropin beta is contraindicated if a patient has an uncontrolled thyroid or adrenal disorder. Regulatory requirements state that patients must be evaluated for hypothyroidism and receive appropriate specific treatment before starting therapy.

Q: Can Puregon interact with herbal supplements?

Official regulatory prescribing information states that formal drug-drug interaction studies have not been conducted for follitropin beta. Consequently, there is no official documentation regarding interactions with herbal products or supplements.

Q: Are interactions between Puregon and birth control pills described?

Official regulatory prescribing information indicates that formal drug-drug interaction studies have not been conducted to evaluate potential pharmacokinetic effects with other medicinal products, which would include hormonal contraceptives.

Q: How long does one cycle of Puregon treatment usually last?

The typical duration of a treatment cycle depends on the specific indication being treated. For controlled ovarian stimulation, the phase often lasts between 6 to 12 days. For ovulation induction, therapy generally should not exceed 35 days. Treatment for men may require several months before an improvement in sperm production is expected.

How to Store and Dispose of Пурегон (Puregon)

Storage and disposal must strictly follow official regulatory instructions to maintain the medicine's stability and safety.

---

Storage Requirements

Condition	Requirement
Unopened Storage	Store in a refrigerator between 2 C and 8 C (36 F to 46 F).
Freezing	Do not freeze the medicine under any circumstances.
Light Protection	Store in the original container to protect it from light.
In-Use Shelf-Life	A punctured cartridge must be used within 28 days.
In-Use Temperature	The cartridge may be stored at a temperature not exceeding 25 C during the 28-day period.
Child Safety	Keep out of the sight and reach of children.

---

Disposal Instructions

Unused or expired medicinal product must be disposed of in accordance with local requirements. Used syringes and needles must be placed into an appropriate puncture-resistant container for safe handling.